Universal Flu Vaccine Candidate Advances Toward Human Trials
Cleveland Clinic researchers report promising results in animal models, aiming for human trials within 1-3 years.
- The experimental vaccine showed strong immune responses and protection against multiple flu strains in mice and ferrets.
- Developed using the COBRA method, the vaccine includes proteins from eight different influenza strains.
- Researchers aim to create a vaccine that offers broad protection and lasts multiple seasons.
- The vaccine could potentially end the need for annual flu shots and protect against pandemic strains like H5N1.
- Human clinical trials are expected to begin within the next one to three years.
UPI 
IFLScience 
Technology Networks 